InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, also called C-Lock, retains biologics, that are applied locally behind the blood brain barrier, in the central nervous system (CNS) and once they leave the CNS, degrades them rapidly in the systemic compartment. Thereby it significantly improves local CNS therapy, a challenging task with regards to achieving high local concentration (for efficacy) and low systemic footprint (to reduce potential side effects). Especially the peripheral side effects still limit various promising candidates for the treatment of brain cancer or other neurological diseases.
Company Details
- Employees
- 11
- Founded
- -
- Industry
- Biotechnology
- Website
- http://www.incephalo.com
Incephalo Questions
Incephalo's website is http://www.incephalo.com
Incephalo's LinkedIn profile is https://www.linkedin.com/company/incephalo
Incephalo has
11 employees.
View email and phone details for 11
employees at Incephalo.
Incephalo's industry is
Biotechnology
Incephalo's top competitors are
Adularia,
Avrion Therapeutics,
Akribion Therapeutics,
Tq Therapeutics,
Mayr Biomedtech Consulting,
Alentis Therapeutics,
Cellestia Biotech,
Tecregen Ag,
Araris Biotech Ag,
Fundamental Pharma.
Incephalo's categories are Biotechnology
Incephalo's founding year is 2021
